Zobrazeno 1 - 7
of 7
pro vyhledávání: '"James A. Matriano"'
Publikováno v:
Pharmaceutical Research. 28:159-165
To evaluate the clinical PK/PD of PTH(1-34) delivered by a novel transdermal drug-coated microneedle patch system (ZP-PTH) for the treatment of osteoporosis.Phase 1 PK studies evaluated the effect of site of administration, patch wear time and dose i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb1151aa81a354f357ca79b96cf5dab2
https://doi.org/10.1007/s11095-010-0192-9
https://doi.org/10.1007/s11095-010-0192-9
Autor:
Juanita A. Johnson, Wendy A. Young, Michel J. N. Cormier, James A. Matriano, Kofi Nyam, Peter E. Daddona, Margaret Buttery
Publikováno v:
Pharmaceutical Research. 19:63-70
Purpose. We evaluated the Macroflux® microprojection array patch technology as a novel system for intracutaneous delivery of protein antigens.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa24745d660038f4a8dce824fe8b7e8a
https://doi.org/10.1023/a:1013607400040
https://doi.org/10.1023/a:1013607400040
Autor:
James A. Matriano, Michael A. Bolognese, Jose R. Zanchetta, Pedro A. Garcia-Hernandez, Felicia Cosman, Karen Sees, Peter E. Daddona, Kim Gaumer, Nancy E Lane
Publikováno v:
The Journal of clinical endocrinology and metabolism. 95(1)
Treatment of osteoporosis with an anabolic agent, teriparatide [human PTH 1-34 (TPTD)], is effective in reducing incident fractures, but patient resistance to daily sc injections has limited its use. A novel transdermal patch, providing a rapid, puls
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23e1e57a2fcb37f2b9e2881c0404d4c8
https://pubmed.ncbi.nlm.nih.gov/19858319
https://pubmed.ncbi.nlm.nih.gov/19858319
L3T4 (CD4+) cells that mediate contact sensitivity to trinitrochlorobenzene express I-A determinants
Publikováno v:
Cellular Immunology. 135:27-41
The present study has further characterized the T cell-mediated inflammatory response of contact sensitivity (CS) to the hapten trinitrochlorobenzene (TNCB) in mice. A discernible CS response was found to be induced as early as 2 days after epicutane
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b269d0c9b5685ab09a55efd5bf7b43d
https://doi.org/10.1016/0008-8749(91)90251-6
https://doi.org/10.1016/0008-8749(91)90251-6
Autor:
Michele M, Kosiewicz, Anasuya, Krishnan, Mark T, Worthington, James A, Matriano, William G, Ross
Publikováno v:
European journal of immunology. 32(6)
Inducing apoptosis of activated lymphocytes via Fas ligand (FasL, CD95) may be a useful strategy for the treatment of autoimmune diseases mediated by pathogenic T cells. We propose that B cells may be ideal tools for effective delivery of a FasL-medi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0028e0f3898b40753360ab578843ea7d
https://pubmed.ncbi.nlm.nih.gov/12115651
https://pubmed.ncbi.nlm.nih.gov/12115651
Autor:
James A, Matriano, Michel, Cormier, Juanita, Johnson, Wendy A, Young, Margaret, Buttery, Kofi, Nyam, Peter E, Daddona
Publikováno v:
Pharmaceutical research. 19(1)
We evaluated the Macroflux microprojection array patch technology as a novel system for intracutaneous delivery of protein antigens.Macroflux microprojection array systems (330-microm micro-projection length, 190 microprojections/cm2, 1- and 2-cm2 ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9fa824321d54659c4c07e42581f73cb1
https://pubmed.ncbi.nlm.nih.gov/11837701
https://pubmed.ncbi.nlm.nih.gov/11837701
Publikováno v:
European Journal of Immunology. 32:1679
Inducing apoptosis of activated lymphocytes via Fas ligand (FasL, CD95) may be a useful strategy for the treatment of autoimmune diseases mediated by pathogenic T cells. We propose that B cells may be ideal tools for effective delivery of a FasL-medi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f444cf2e669d8f86d6345dbc51c50daa
https://doi.org/10.1002/1521-4141(200206)32:6<1679::aid-immu1679>3.0.co
https://doi.org/10.1002/1521-4141(200206)32:6<1679::aid-immu1679>3.0.co